Abstract
Anticoagulation remains the cornerstone of treatment in patients with deep vein thrombosis (DVT). While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants have provided clinicians with an expanding set of therapeutic options for DVT. This review summarizes the pharmacology and clinical trial results of these new oral anticoagulants. Several practical considerations to the use of these oral anticoagulants including issues related to adherence, monitoring, and reversal are also discussed.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP study group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657–60.
Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722–7. doi:10.1111/j.1525-1497.2006.00458.x.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8. doi:10.1161/01.CIR.0000078468.11849.66.
Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost. 2011;106(3):405–15. doi:10.1160/TH11-02-0132.
Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28(4):465–76. doi:10.1007/s11239-009-0309-3.
Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Archives of internal medicine. 2004;164(1):17–26. doi:10.1001/archinte.164.1.17.
Vazquez SR, Freeman A, VanWoerkom RC, Rondina MT. Contemporary issues in the prevention and management of postthrombotic syndrome. Ann Pharmacother. 2009;43(11):1824–35. doi:10.1345/aph.1M185.
Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102(4):688–93. doi:10.1160/TH09-04-0266.
Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clinical and applied thrombosis/Hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2008;14(4):393–8. doi:10.1177/1076029608317942.
Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res. 2012;129(3):392–400. doi:10.1016/j.thromres.2011.12.014.
Brenner B, Hoffman R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood reviews. 2011;25(5):215–21. doi:10.1016/j.blre.2011.04.003.
Cohen AT, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012;107(6):1035–43. doi:10.1160/TH11-12-0859.
Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. European journal of internal medicine. 2012;23(8):692–5. doi:10.1016/j.ejim.2012.10.001.
Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72(13):1739–53. doi:10.2165/11635730-000000000-00000.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S. doi:10.1378/chest.11-2301. These evidence-based guidelines discuss the treatment of DVT..
Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016–23. doi:10.1182/blood-2011-10-378950. This outstanding review highlights patient characteristics important to consider when choosing between new or established anticoagulants..
Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British journal of clinical pharmacology. 2010;70(5):703–12. doi:10.1111/j.1365-2125.2010.03753.x.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510. doi:10.1056/NEJMoa1007903.
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug metabolism and disposition: the biological fate of chemicals. 2008;36(2):386–99. doi:10.1124/dmd.107.019083.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52. doi:10.1056/NEJMoa0906598.
Schulman S, Kakkar AK, Schellong S, Goldhaber SZ, Henry E, Mismetti P et al., editors. A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Presented at the 53rd Annual American Society of Hematology Meeting; 2011.
Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18. doi:10.1056/NEJMoa1113697.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi:10.1056/NEJMoa1007432.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013. doi:10.1056/NEJMoa1302507.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. doi:10.1056/NEJMoa1207541.
Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287–94. doi:10.1111/jth.12230.
Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–71. doi:10.1160/TH10-05-0328.
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S–50S. doi:10.1378/chest.11-2298.
Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245–52. doi:10.1111/jth.12096. This review discussed important aspects of the laboratory assessment of novel oral anticoagulants..
Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141–5. doi:10.1002/ajh.23202. This review discussed important aspects of the reversal of novel oral anticoagulants..
Nitzki-George D, Wozniak I, Caprini JA. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother. 2013;47(6):841–55. doi:10.1345/aph.1R724.
Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G, et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013;11(1):177–9. doi:10.1111/jth.12038.
Cushman M. Treating acute venous thromboembolism: shift with care. NEJM. 2013. doi:10.1056/NEJMe1307413.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86(1):452–63.
Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Archives of internal medicine. 2004;164(20):2260–5. doi:10.1001/archinte.164.20.2260.
Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006;32(7):651–8. doi:10.1055/s-2006-951293.
Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs & aging. 2006;23(8):651–71.
Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979–87. doi:10.1111/j.1538-7836.2012.04866.x.
Acknowledgments
This work was supported by the National Institutes of Health and the National Institute of Aging (K23HL092161 and R03AG040631 to M.T.R.). We thank Ms. Alex Greer for her excellent editorial assistance.
Compliance with Ethics Guidelines
ᅟ
Conflict of Interest
Timothy Vo declares that he has no conflict of interest.
Sara Vazquez declares that she has no conflict of interest.
Matthew T. Rondina has received honoraria from Boehringer Ingelheim for Advisory Board participation.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Peripheral Vascular Disease
Rights and permissions
About this article
Cite this article
Vo, T., Vazquez, S. & Rondina, M.T. Current State of Anticoagulants to Treat Deep Venous Thrombosis. Curr Cardiol Rep 16, 463 (2014). https://doi.org/10.1007/s11886-013-0463-2
Published:
DOI: https://doi.org/10.1007/s11886-013-0463-2